Yu.S. Zakharenkova

Yu.S. Zakharenkova

Auto-generated profile, based on publicly available information

Yu.S. Zakharenkova

Herzen Moscow Oncology Research Center

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2017 in World Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
MSMarina I. Savelyeva
Marina I. Savelyeva
JPJulia S. Panchenko
Julia S. Panchenko
IUIrina A. Urvantseva
Irina A. Urvantseva
AIAnna K. Ignatova
Anna K. Ignatova
IPIrina V. Poddubnaya
Irina V. Poddubnaya
Tamoxifen is the selective modulator of estrogen receptors. Nowadays, it is widely used in the treatment of ER(+) breast cancer and substantially decreases the risks of recurrence and disease progression. However, high interindividual variability in response is observed, calling for a personalized approach to tamoxifen treatment. Tamoxifen is metabolized by cytochrome P450, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. The effectiveness and success of treatment depends largely on concentrations of the active tamoxifen metabolites in blood plasma. Polymorphisms in the genes encoding these enzymes are proposed to influence on pharmacokinetics and pharmacodynamics of tamoxifen. Therefore, pharmacogenetic approach may form the basis of personalized treatment of breast cancer. In this systematic review, we analyze all current data about the potential use of genotyping of CYP2D6, CYP3A4/5, CYP2B6 to predict an individual response on tamoxifen treatment.

31 July 2025 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
VKVictoria E. Khoronenko
Victoria E. Khoronenko
IKIulia S. Koroleva
Iulia S. Koroleva
ВТВладимир Сергеевич Трифанов
Владимир Сергеевич Трифанов
ВХВиктория Эдуардовна Хороненко
Виктория Эдуардовна Хороненко
INTRODUCTION: Inadequate anaesthetic protection during surgery as well as poor control of postoperative pain are the trigger mechanisms of the surgical stress response, which represents a complex of homeostatic changes that significantly contribute to the development of postoperative complications. OBJECTIVE: The primary objective of this study was to summarize the current data on modern approaches to perioperative analgesia and protection of patients from surgical stress response during major abdominal surgeries. MATERIALS AND METHODS: The review includes sources which meet the objectives of the study and are indexed in the databases of PubMed, Google Scholar, MEDLINE, and eLibrary (for Russian authors). RESULTS: The analysis of the literature clearly identified the risk factors for the development of acute postoperative pain and demonstrated a trend towards combining postoperative analgesic methods. These approaches reduce the need for opioids, effectively modulate in the perioperative period stress response to surgical intervention, and decrease the risk of postoperative complications in abdominal surgery. CONCLUSIONS: Modern approaches to perioperative analgesia when used in a timely and appropriate manner are largely responsible for ensuring adequate patient protection. The trend towards decreasing opioid use during perioperative period suggests the combination of various techniques. Epidural analgesia (EA), erector spinae plane (ESP), quadratus lumborum (QLB), or transversus abdominis plane (TAP) blocks, intravenous lidocaine infusion, and nefopam are effective and complementary components of multimodal perioperative pain management.

9 February 2023 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
EAE.A. Aleksandrova
E.A. Aleksandrova
VKV.E. Khoronenko
V.E. Khoronenko
AMA.S. Malanova
A.S. Malanova
YZYu.S. Zakharenkova
Yu.S. Zakharenkova
PSP.A. Suvorin
P.A. Suvorin
Выполнение торакальных операций помимо технической сложности подобного типа вмешательств характеризуется высоким анестезиологическим риском, который определяется функциональными резервами больного и наличием сопутствующих онкологическому процессу заболеваний. Диагностика инфаркта миокарда в ранние сроки после операции затруднена ввиду использования системной анальгетической терапии и смазанности клинической картины данного состояния, поэтому все большее число международных профессиональных медицинских сообществ рекомендуют для оценки периоперационного сердечно-сосудистого риска, в том числе в некардиальной хирургии, использовать лабораторные маркеры усиления нагрузки на миокард с определением выброса соответствующих биологически активных веществ. ЦЕЛЬ ИССЛЕДОВАНИЯ Проанализировать перспективы внутривенного введения лидокаина в качестве средства адъювантной кардиопротекции во время анестезии и операции у больных раком легкого с сопутствующей сердечно-сосудистой патологией, руководствуясь динамикой уровня N-терминального мозгового натрийуретического белка (NT-proBNP) и клинической картиной в раннем послеоперационном периоде. МАТЕРИАЛ И МЕТОДЫ В исследование включены 30 пациентов в возрасте от 55 до 79 лет с установленным диагнозом локализованного немелкоклеточного рака легкого, имевшие сердечно-сосудистую патологию, которым выполнена операция в объеме сегментэктомии либо лобэктомии. Случайным образом пациенты разделены на две группы: группу лидокаина (пациенты интраоперационно получали лидокаин внутривенно болюсно + через инфузомат) и группу контроля. Оценка NT-proBNP проведена до момента кожного разреза, а также в 1-е и на 3-и послеоперационные сутки. РЕЗУЛЬТАТЫ Сравнительный анализ не показал различий в уровнях NT-proBNP исходно и в 1-е сутки после операции (p=0,065 и p=0,237 соответственно). Существенные, статистически значимые, различия уровней NT-proBNP получены на 3-и сутки послеоперационного периода. В группе контроля этот показатель примерно в 2,3 раза выше (p=0,004). Вместе с тем выявлена прямая связь между уровнем NT-proBNP в 1-е сутки после операции и минимальным и максимальным значениями частоты сердечных сокращений интраоперационно (p=0,02). Клинически признаки ишемии миокарда не зафиксированы. У одного пациента группы контроля развился послеоперационный делирий. ЗАКЛЮЧЕНИЕ На основании результатов проведенного исследования можно рекомендовать внутривенное введение лидокаина в качестве адъювантного средства анестезии при торакальных операциях для кардиопротекции у онкологических пациентов с сердечно-сосудистой патологией. Однако требуются дальнейшие проспективные исследования с увеличением объема выборки больных и строгим соответствием критериям отбора пациентов.

31 December 2025 in Russian Journal of Anesthesiology and Reanimatology
Verified
Journal Article
Closed access
YKYu.S. Koroleva
Yu.S. Koroleva
VKV.E. Khoronenko
V.E. Khoronenko
VTV.S. Trifanov
V.S. Trifanov
The problem of perioperative analgesia for extensive abdominal surgeries remains relevant, as available experience of widespread epidural analgesia revealed limitations and complexities of this approach. Objective. To compare the efficacy and safety of perioperative thoracic epidural analgesia and nefopam therapy (opioid-sparing strategy), and to analyze the impact of analgesia methods on postoperative complications. Material and methods. The study included 60 patients with biliopancreatoduodenal tumors who underwent (gastro)pancreatoduodenectomy (G(PDD)). Patients were randomized into 2 groups: the nefopam group (N, n=30) and the epidural analgesia group (EA, n=30). We assessed course of anesthesia, NRS scores of postoperative pain syndrome at rest and during mobilization, serum glucose and cortisol at different stages of follow-up, opioid requirements, onset of peristalsis and first defecation, postoperative complications. Results. Pain syndrome was less severe in the group N on days 1 and 2 after surgery (p=0.012 and p=0.045). After 2 and 3 days, the need for morphine was significantly lower in group N, where mean dose was 14.42 (95% CI 12.30—16.54) mg/day and 8.60 (95% CI 6.05—11.15) mg/day. In the group EA, these values were 19.33 (95% CI 15.41—23.26) mg/day and 13.92 (95% CI 10.58—17.26) mg/day, respectively (p=0.029 and p=0.012). Independent predictors of pancreatic fistula were high BMI, intraoperative blood loss and postoperative infusion volume. Conclusion. Both techniques allow for adequate pain control after pancreaticoduodenectomy. Nefopam has higher opioid-sparing effect in postoperative period. The impact of perioperative analgesia technique on postoperative complications after pancreaticoduodenectomy requires further investigation.

22 December 2023 in Russian Journal of Oncology
Verified
Journal Article
Open access
IZIuliia S. Zakharenkova
Iuliia S. Zakharenkova
VKVictoria E. Khoronenko
Victoria E. Khoronenko
VTVladimir S. Trifanov
Vladimir S. Trifanov
ЗСЗахаренкова Юлия Сергеевна
Захаренкова Юлия Сергеевна
ХЭХороненко Виктория Эдуардовна
Хороненко Виктория Эдуардовна
BACKGROUND: Pancreatoduodenal resections are one of the most traumatic and technically complex interventions in abdominal surgery. The correct anesthetic management and pain relief allow to substantially reduce the risk of perioperative complications, which remains high even in high-volume oncology centers with extensive experience. Finding new components and methods of anesthesia combined with evaluation of their effectiveness and safety remains a pressing issue. AIM: To evaluate the efficacy and safety of using intravenous lidocaine infusion as a component of anesthesia and postoperative analgesia in cancer patients during pancreatoduodenal resection. MATERIALS AND METHODS: We analyzed the course of anesthesia, operation and postoperative period of 43 patients (mean age 63.2±7.1 years) undergoing pancreaticoduodenectomy. For the purposes of the study, patients were randomly divided into 2 groups, based on anesthesia method: for the first group (n=19) we used epidural analgesia as a component of perioperative anesthesia, for the second group (n=24) we used prolonged intravenous infusion of lidocaine at an average dose of 1 mg/(kg×h). We analyzed the severity of pain syndrome according to Numeric rating scale for pain in postoperative period, as well as opioid requirement, the time of gastrointestinal function recovery, and post-operative complications frequency. In order to prevent systemic toxicity, drug monitoring was carried out — the determination of the plasma concentration of lidocaine. RESULTS: Perioperative opioid requirement was comparable between groups, with no statistically significant differences observed. The degree of pain syndrome according to the Numeric rating scale for pain did not differ statistically, except for the number of points during activation on day 3: 4.00 (95% confidence interval 3.49–4.51) for epidural analgesia group, compared to 3.12 (95% confidence interval 2.64–3.61) for lidocaine infusion group, p=0.014. There was also a statistically significant increase in infusion volume for epidural analgesia group compared to lidocaine infusion group [8.83 ml/(kg×h) (Q1=7.90; Q3=10.06) and 7.33 ml/(kg×h) (Q1=6.28–Q3=8.49) respectively, p=0.034], as well as a greater need for intraoperative vasopressor support among the patients [15 (78.9%) and 10 (43.5%) respectively, p=0.029]. In the lidocaine group, the time to onset of peristalsis was significantly shorter than in the epidural analgesia group [median 48.0 h (Q1=48.00; Q3=72.00) compared to median 60.0 h (Q1=36.00; Q3=64.50) respectively, p=0.042]. The frequency of postoperative complications did not differ between the groups. CONCLUSION: Based on a comparative analysis of the study results, it can be concluded that prolonged intravenous infusion of lidocaine, as a component of perioperative anesthetic protection during pancreatoduodenal resections, is safe and comparable in terms of analgesic efficacy to epidural blockade.

18 April 2024 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
VKV.E. Khoronenko
V.E. Khoronenko
YZYu.S. Zakharenkova
Yu.S. Zakharenkova
VVV.V. Varvarin
V.V. Varvarin
DSD.S. Sheremet
D.S. Sheremet
MSM.M. Shemetova
M.M. Shemetova
DSD.V. Sidorov
D.V. Sidorov
This article presents a clinical case of the first successful autotransplantation of the liver at the P.A. Herzen Moscow Oncological Research Institute, accompanied by massive blood loss and severe post-resection liver failure. The patient diagnosed with «stage IIIB hepatocellular carcinoma, T4N0M0» was admitted for surgical treatment. According to abdominal computed tomography, the left lobe of the liver was completely replaced by a lesion measuring 25x14x24 cm. Given the localization and spread of the tumor process, a decision was made to perform an extracorporeal stage of liver resection followed by autotransplantation. The intraoperative period was complicated by massive blood loss of 19.000 ml. In the early postoperative period, the patient was diagnosed with severe post-resection liver failure, requiring correction with extracorporeal detoxification methods (ultrahemodiafiltration, plasmapheresis). On the 17th day, the patient was transferred to a general ward in satisfactory condition and discharged from the clinic after 28 days.